title: Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
abstract: Multiple sclerosis is a chronic disease requiring lifelong treatment with disease-modifying drugs that aim to prevent relapses and slow the progression of disability. The established first-line treatments for multiple sclerosis all require regular injections, and real-world observations suggest that long-term adherence to treatment is low. Indeed, poor adherence to disease-modifying drug treatment has been associated with poorer clinical outcomes. Autoinjectors have been developed to improve the success of self-injection, whilst also making injections more comfortable for patients, with the aim of minimizing obstacles to treatment adherence. RebiSmart™ is a new electronic autoinjector for subcutaneous administration of interferon β-1a (Rebif®) that includes several unique features designed to further reduce barriers to adherence, including a dosing log and adjustable comfort settings.
authors: Department of Neurology, University of British Columbia, Rm S159, 2211 Wesbrook Mall, Vancouver V6T 2B5, BC, Canada. vdev@shaw.ca
authors: Virginia A
authors: VA
authors: Devonshire
authors: Elisabetta
authors: E
authors: Verdun di Cantogno
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D004867:Equipment Design; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage* / Q000627:therapeutic use; D055118:Medication Adherence; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012646:Self Administration
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a